USA - NASDAQ:IRON - US2546041011 - Common Stock
The current stock price of IRON is 70.28 USD. In the past month the price increased by 17.25%. In the past year, price increased by 47.18%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 21.84 | 408.50B | ||
AMGN | AMGEN INC | 13.51 | 158.61B | ||
GILD | GILEAD SCIENCES INC | 15.28 | 146.73B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 24.86 | 107.98B | ||
REGN | REGENERON PHARMACEUTICALS | 12.35 | 59.76B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.08B | ||
ARGX | ARGENX SE - ADR | 86.19 | 48.90B | ||
ONC | BEONE MEDICINES LTD-ADR | 5.67 | 38.56B | ||
INSM | INSMED INC | N/A | 34.20B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.55B | ||
NTRA | NATERA INC | N/A | 23.62B | ||
BIIB | BIOGEN INC | 9.43 | 22.13B |
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. The company is headquartered in Watertown, Massachusetts and currently employs 84 full-time employees. The company went IPO on 2020-08-12. The firm's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. The company is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
DISC MEDICINE INC
321 Arsenal Street, Suite 101
Watertown MASSACHUSETTS US
Employees: 125
Phone: 16176749274
The current stock price of IRON is 70.28 USD. The price increased by 3.52% in the last trading session.
The exchange symbol of DISC MEDICINE INC is IRON and it is listed on the Nasdaq exchange.
IRON stock is listed on the Nasdaq exchange.
18 analysts have analysed IRON and the average price target is 101.72 USD. This implies a price increase of 44.74% is expected in the next year compared to the current price of 70.28. Check the DISC MEDICINE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
DISC MEDICINE INC (IRON) has a market capitalization of 2.44B USD. This makes IRON a Mid Cap stock.
DISC MEDICINE INC (IRON) currently has 125 employees.
DISC MEDICINE INC (IRON) has a support level at 64.08. Check the full technical report for a detailed analysis of IRON support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
IRON does not pay a dividend.
DISC MEDICINE INC (IRON) will report earnings on 2025-11-10, before the market open.
DISC MEDICINE INC (IRON) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.47).
The outstanding short interest for DISC MEDICINE INC (IRON) is 8.11% of its float. Check the ownership tab for more information on the IRON short interest.
ChartMill assigns a technical rating of 10 / 10 to IRON. When comparing the yearly performance of all stocks, IRON is one of the better performing stocks in the market, outperforming 86.95% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to IRON. IRON scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months IRON reported a non-GAAP Earnings per Share(EPS) of -4.47. The EPS decreased by -24.17% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -21.86% | ||
ROE | -23.67% | ||
Debt/Equity | 0.05 |
18 analysts have analysed IRON and the average price target is 101.72 USD. This implies a price increase of 44.74% is expected in the next year compared to the current price of 70.28.